The FDA has approved Onyda XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD – Tris Pharma
Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, announced the FDA has approved Onyda XR (clonidine hydrochloride),… read more.
